In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1504-1510

  Chen, Ying Yi ^a   Finlay, Graeme J ^a   Kirker, James A ^a   Marshall, Elaine S ^a   Richardson, Emma ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Colon; DNA damage; H2AX; Senescence; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HISTONE H2AX; N [2 (DIMETHYLAMINO)ETHYL] 2,6 DIMETHYL 1 OXO 1,2 DIHYDROBENZO[B] 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; SN 28049; UNCLASSIFIED DRUG; N (2 (DIMETHYLAMINO)ETHYL) 2,6 DIMETHYL 1 OXO 1,2 DIHYDROXYBENZO(B) 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; N-(2-(DIMETHYLAMINO)ETHYL)-2,6-DIMETHYL-1-OXO-1,2-DIHYDROXYBENZO(B)-1,6-NAPHTHYRIDINE-4-CARBOXAMIDE; NAPHTHYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORPHOLOGY; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HISTONE PHOSPHORYLATION; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MITOSIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE DRUG DOSE; ANIMAL; C57BL MOUSE; CELL CYCLE; COLON TUMOR; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; IN SITU NICK-END LABELING; MICE; MICE, INBRED C57BL; NAPHTHYRIDINES; PHOSPHORYLATION;

EID: 84856064002     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9509-0     Document Type: Article

References (12)

1. Nelson EM, Tewey K, Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)- methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81:1361-1365 (Pubitemid 14173469)
2. Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer Clin Oncol 10:539-549
3. Arlin ZA (1983) Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia. Cancer Treat Rep 67:967-970 (Pubitemid 14208694)
4. Baguley BC, Zhuang L, Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino) ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol 36:244-248
5. Deady LW, Rogers ML, Zhuang L, Baguley BC, Denny WA (2005) Synthesis and cytotoxic activity of carboxamide derivatives of benzo [b][1, 6]naphthyridin-(5H) ones. Bioorg Med Chem 13:1341-1355 (Pubitemid 40164617)
6. Bu X, Chen J, Deady LW, Smith CL, Baguley BC, Greenhalgh D, Yang S, Denny WA (2005) Synthesis and cytotoxic activity of N-[(alkylamino) alkyl]-carboxamide derivatives of 7-oxo-7H-benz [de]anthracene, 7-oxo-7H-naphtho[1, 2, 3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. Bioorg Med Chem 13:3657-3665
7. Bridewell DJ, Porter AC, Finlay GJ, Baguley BC (2008) The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol 62:753-762
8. Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC (2010) Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs, in press
9. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35:2434-2439
10. Lukka PB, Paxton JW, Kestell P, Baguley BC (2010) Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol 65:1145-1152
11. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi JCIN (2009) Pmid: persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11:973-979
12. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61 (Pubitemid 46067386)